Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

Study Identifier:
APG-20-OLE
ClinicalTrials.gov Identifier:
NCT06679270
EudraCT Identifier:
N/A
Study Contact Information:
+3905212791 or [email protected]
Recruiting

Study Details

Medical Condition
  • Familial Partial Lipodystrophy
Study Drug
  • Drug: Metreleptin
Date
Oct 2024 - Mar 2028
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 13+ years
Requirements Information
Healthy Volunteers
No

Protocol Summary

This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy

Study Locations

Location
Status
Location
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Status
Not yet recruiting
Location
University of Michigan
Ann Arbor, Michigan, United States, 48109
Status
Recruiting
Location
UT Southwestern Medical Center
Dallas, Texas, United States, 75390
Status
Not yet recruiting
Location
The Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Status
Recruiting